Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Heparin Immunogenicity Guidance Addresses ANDA Approvals, Brand Changes

Executive Summary

Guidance formalizes five criteria FDA used in making a “sameness” determination for Momenta/Sandoz’s enoxaparin ANDA and lays out an approach to assessing the effect of post-approval NDA changes on a product’s immunogenicity without the need for clinical trials.

You may also be interested in...



Lilly Preps To File A Rival To Lantus, But Safety Remains In Question

Eli Lilly’s novel basal insulin peglispro demonstrated superiority to Sanofi’s Lantus in three Phase III trials on blood sugar control, but the insulin also increased triglycerides and liver enzymes in patients.

Lilly Preps To File A Rival To Lantus, But Safety Remains In Question

Eli Lilly’s novel basal insulin peglispro demonstrated superiority to Sanofi’s Lantus in three Phase III trials on blood sugar control, but the insulin also increased triglycerides and liver enzymes in patients.

FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics

The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS056051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel